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Driving under the influence of psychoactive substances is a major cause of motor vehicle
crashes. The identification and quantification of substances most frequently involved in
impaired-driving cases in a single analytic procedure could be an important asset in
forensic toxicology. In this study, a highly sensitive and selective liquid chromatography
(LC) approach hyphenated with Orbitrap high-resolution mass spectrometry (HRMS) was
developed for the quantification of the main drugs present in the context of driving under
the influence of drugs (DUID) using 100 µL of whole blood. This procedure involves a
simple sample preparation and benefit from the selectivity brought by parallel reaction
monitoring (PRM) allowing to solvemost DUID cases using a singlemulti-analyte injection.
The method was fully validated for the quantification of the major classes of psychoactive
substances associated with impaired-driving (cannabinoids, cocaine and its metabolites,
amphetamines, opiates and opioids, and the major benzodiazepines and z-drugs). The
validation guidelines set by the “Société Française des Sciences et des Techniques
Pharmaceutiques” (SFSTP) were respected for 22 psychoactive substances using 15
internal standards. Trueness was measured to be between 95.3 and 107.6% for all the
tested concentrations. Precision represented by repeatability and intermediate precision
was lower than 12% while recovery (RE) and matrix effect (ME) ranged from 49 to
105% and from −51 to 3%, respectively. The validated procedure provides an efficient
approach for the simultaneous and simple quantification of the major drugs associated
with impaired driving benefiting from the selectivity of PRM.
Keywords: parallel reaction monitoring, quantitative analysis, whole blood, driving under the influence of drugs,
multi-analyte
INTRODUCTION
Road crashes are a worldwide public health issue, causing a significant number of deaths and
injuries each year. Indeed, 1.25 million people died and about 50 million were injured in road
traffic crashes in 2015 according to the World Health Organization (2015). In addition, in Europe
almost 25% of adults reported at least one instance of illicit drug consumption in their life
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(Liakoni et al., 2018). These two issues are closely linked, since
one of the major causes of road crashes is the consumption of
psychotropic substances, including drugs and alcohol, resulting
in driving impairment (Elliott et al., 2009; Favretto et al., 2018).
For instance, in Norway, at least 21% of traffic crashes were
related to either alcohol or drug use between 2005 and 2015
(Valen et al., 2019). The total number of victims of fatal crashes
has significantly decreased in the past years in Western countries
thanks to efficient prevention. Yet, the use of medicinal or illicit
drug and/or alcohol is an increasing phenomenon in Europe
(Snenghi et al., 2018; Pelletti et al., 2019), and the percentage
of fatal crashes due to the driver’s impairment remain constant
(between 17 and 22% from 1995 to 2017) in Switzerland [Office
Fédéral de la Statistique (OFS), 2018].
Due to the large variety of drugs and pharmaceuticals with
various psychoactive effects, there is a need for medical experts
to establish solid statement on a potential driving-impairment
and for official quantification of drugs and alcohol levels in
blood (Martin et al., 2017). In Switzerland, a zero tolerance with
technical cut-offs is implemented regarding classical drugs of
abuse (DoA) toward drivers (1.5 ng/ml for THC and 15 ng/ml for
morphine, cocaine, amphetamine, methamphetamines, MDEA,
andMDMA) (Walsh et al., 2004; Steuer et al., 2016). The situation
is more complex regarding the consumption of medicinal
drugs and the toxicological interpretation of their concentration
(Ravera et al., 2012). With respect to the law, the driving
capability under pharmaceuticals is concomitantly determined
by a “three pillars expertise” including police assessment, medical
expertise, and toxicological analysis in blood, being the biological
matrix of reference regarding toxicological interpretation (Steuer
et al., 2014). The Swiss Federal Roads Office (FEDRO) defines
a list of controlled substances that the laboratories must be
able to quantify in the context of external quality controls
(EQCs) in whole blood regarding driving under the influence
of drugs (DUID). Those recommendations, associated with
the knowledge of drug prevalence among suspected drivers,
were used to establish a list of substances of interest in the
present study.
Improvements regarding instrumentation, notably brought
on by the developments of Orbitrap technology, offer new
opportunities in terms of analytical strategies (Hoffman et al.,
2018; Joye et al., 2019). Indeed, various Orbitrap-based parallel
reaction monitoring (PRM) applications have been reported,
especially in the field of proteomics (Domon and Gallien, 2015;
Rauniyar, 2015; Bourmaud et al., 2016). In a PRM acquisition,
a precursor selected by a quadrupole is fragmented in a higher-
energy collisional dissociation (HCD) cell (Ronsein et al., 2015).
Following this experiment, all product ions are simultaneously
acquired in the high-resolution Orbitrap analyzer. Up to now,
the use of triple-quadrupole (QQQ) using Selected Reaction
Monitoring (SRM) has been the gold standard regarding targeted
quantitative analyses (Hopfgartner et al., 2004; Rauniyar, 2015).
However, SRM and PRM have comparable sensitivity with
similar linearities, dynamic ranges, precision, and repeatability
(Domon and Gallien, 2015; Joye et al., 2020). Yet Orbitrap-
based PRM offers further advantages, since the acquisition of all
selected precursors’ fragments is performed, thereby limiting the
a priori information required for method development. Indeed,
the selection of quantifying ions is only necessary during the data
processing step once the whole fragmentation spectra is acquired.
Moreover, HRMS provides a higher specificity, allowing for the
separation of the background ions from the targeted molecules
(Ronsein et al., 2015).
Drug quantification can easily benefit from the PRM
specificities that have been enlightened for proteomic
applications. Even though this strategy is relatively recent
regarding illicit drug and pharmaceuticals analyses in
toxicology, it has received a growing interest. Indeed, PRM
quantification has been reported for the quantitative analysis
of abiraterone (Bhatnagar et al., 2018), beclabuvir (Jiang et al.,
2017), anticoagulant rodenticides (Gao et al., 2018), and sterols
(Schott et al., 2018). Regarding drugs of abuse, a first application
has been described for the quantification of cannabinoids in
whole blood (Joye et al., 2020).
Herein, we present a validated single multi-analyte procedure
for the quantification of the main substances regarding DUID
cases using 100 µL of whole blood. The quantified substances
were selected based on the FEDRO list and the prevalence of
substances consumed by the drivers in Switzerland (Augsburger
and Rivier, 1997; Augsburger et al., 2005; Senna et al., 2010).
The validated approach uses the advantages provided by HRMS
and especially PRM for the simultaneous quantification of 22
DoA and pharmaceuticals alongside 15 internal standards (IS),
enabling the solving of most DUID cases with a single injection
and a simple sample preparation.
MATERIALS AND METHODS
Standards and Reagents
Water, methanol, formic acid (FA), and ammonium formiate
were furnished by Biosolve. Drugs standard were purchased
from Cerilliant or Lipomed, at either 1 mg/ml or 100µg/ml.
External quality controls (ECQ) were purchased fromMedidrug,
ACQ Science, or Clincheck. Blank lyophilized whole blood was
acquired from ACQ Science.
Solution Preparation
Standard solutions containing tetrahydrocannabinol (THC), 11-
Nor-9-carboxy-THC (THC-COOH), alprazolam, amphetamine,
methamphetamine, 3,4-methylendioxymethamphetamine
(MDMA), 3,4-methylene dioxy-amphetamine (MDA),
methylphenidate, cocaine, cocaethylene, lorazepam,
bromazepam, zolpidem, benzoylecgonine, morphine, codeine,
methadone, tramadol, O-desmethyltramadol, diazepam,
nordiazepam, oxazepam were prepared for calibration
curve and internal quality control (IQC) preparation.
In parallel, solutions containing THC-D3, THC-COOH-
D9, cocaine-D3, benzoylecgonine-D3, amphetamine-D8,
MDMA-D5, methylphenidate-D10, morphine-D3, codeine-D3,
methadone-D3, tramadol13C-D3, O-desmethyltramadol-D6,
nordiazepam-D5, alprazolam-D5, and zolpidem-D6 were
prepared as internal standard (IS) solutions.
Calibration samples were prepared by spiking lyophilized
whole blood at 5 concentration levels (Table 1). IS were added to
































TABLE 1 | Calibration levels and quantification parameters (IS, polarity, parent ion m/z, and quantifier ions) for the substances of interest. The calibration ranges are in adequacy with the legal thresholds and the
therapeutic ranges.
Calibration levels (ng/ml) Quantification parameters







IS parent ion → quantifier ion
THC 1 2 5 10 20 + 315.2319 → 193.1222 123.0440 THC-D3 10 318.2507 → 196.1413
THC-COOH 5 10 25 50 100 – 343.1915 → 245.1546 191.1068 THC-COOH-D9 100 352.2479 → 254.2108
Cocaine 10 20 50 100 200 + 304.1543 → 182.1177 82.0657 Cocaine-D3 100 307.1731 → 185.1364
Cocaethlyene 50 100 250 500 1,000 + 318.1699 → 196.1333 82.0651 Cocaine-D3 100 307.1731 → 185.1364
Benzoylecgonine 50 100 250 500 1,000 + 290.1387 → 168.1020 105.0338 Benzoylecgonine-D3 100 293.1575 → 171.1204
Amphetamine 10 20 50 100 200 + 136.1121 → 91.0547 119.0857 Amphetamine-D8 100 144.1623 → 97.0921
Methamphetamine 10 20 50 100 200 + 150.1277 → 91.0547 119.0857 Amphetamine-D8 100 144.1623 → 97.0921
MDA 10 20 50 100 200 + 180.1019 → 133.0648 105.0702 MDMA-D5 100 199.1489 → 165.0877
MDMA 10 20 50 100 200 + 194.1175 → 163.0753 135.0441 MDMA-D5 100 199.1489 → 165.0877
Methylphenidate 10 20 50 100 200 + 234.1488 → 84.0813 56.0503 Methylphenidate-D10 100 244.2116 → 93.1376
Morphine 5 50 500 1,000 2,000 + 286.1438 → 201.0908 229.0858 Morphine-D3 1,000 289.1626 → 201.0906
Codeine 5 50 500 1,000 2,000 + 300.1594 → 215.1061 58.0659 Codeine-D3 1,000 303.1783 → 215.1061
Methadone 5 50 500 1,000 2,000 + 310.2165 → 105.0339 219.1167 Methadone-D3 1,000 313.2354 → 105.0337
Tramadol 5 50 500 1,000 2,000 + 264.1958 → 58.0659 – Tramadol-13C-D3 1,000 269.2287 → 58.0657
O-Desmethyltramadol 5 50 500 1,000 2,000 + 250.1801 → 58.0659 – O-Desmethyltramadol-D6 1,000 256.2178 → 64.1033
Diazepam 100 200 500 1,000 2,000 + 285.0789 → 154.0417 193.0885 Nordiazepam-D5 1,000 276.0947 → 140.0258
Nordiazepam 100 200 500 1,000 2,000 + 271.0633 → 140.0262 165.0212 Nordiazepam-D5 1,000 276.0947 → 140.0258
Oxazepam 100 200 500 1,000 2,000 + 287.0582 → 241.0527 104.0498 Nordiazepam-D5 1,000 276.0947 → 140.0258
Lorazepam 20 50 100 150 300 + 321.0192 → 229.0527 163.0055 Alprazolam-D5 100 314.1215 → 286.1018
Bromazepam 20 50 100 150 300 + 316.0080 → 182.0839 209.0945 Alprazolam-D5 100 314.1215 → 286.1018
Alprazolam 5 10 25 50 100 + 309.0902 → 281.0707 274.1208 Alprazolam-D5 100 314.1215 → 286.1018
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reach a final concentration of 10 (THC-D3), 100, or 1,000 ng/ml
depending on the specific calibration range.
Sample Pre-treatment
IS solutions were spiked in Eppendorfs and evaporated to dryness
before adding 100 µL of whole blood. The extraction was then
performed by protein precipitation using 300 µL of methanol.
After centrifugation for 10min at 14,000 rpm, the upper
methanolic phase was transferred into a new Eppendorf and
evaporated to dryness under a nitrogen flow. Reconstitution was
performed using 100 µL of 1:9 methanol: water and 10 µL were
injected into the LC-HRMS system (Supplemental Figure 1).
LC-HRMS Method
A Thermo Scientific Ultimate 3000 LC system with a
Phenomenex 2.6µm C18 (10 cm × 2.1mm) maintained at
45◦C was used for chromatographic separation. Mobile phases
were composed of A, ammonium formate 10mM at pH 3.3,
and B, methanol with 0.1% FA. Phase B was ramped linearly
from 2 to 98% over 7.5min. The column was then washed
at 98% of B for 3.5min, followed by a 6min re-equilibration
at 2% of B at 300 µL/min for a total analysis run of 17min.
The LC was coupled to a Q Exactive Plus system (Thermo
Scientific, Bremen, Germany) via a heated electro spray
ionization (ESI) source (H-ESI II probe, Thermo Scientific).
The ionization spray voltage was set to 3 kV, sheath gas
flowrate was set to 40, and auxiliary gas flowrate to 10 (both
in arbitrary units). The method functioned in PRM, using
an inclusion list containing the exact mass of the parent ion
and the retention time windows for the different analytes. A
polarity switch in negative was performed at 7.5min for the
specific detection of THC-COOH with a switch back in positive
polarity at 8.7min for the detection of THC. Resolution was
set to 17,500 for the HCD fragmentation performed using an
NCE at 50 eV with an AGC target of 1e5 and a maximum IT of
100 ms.
Method Validation
The validation criteria used to evaluate the analytical process
was based on the directives of the “Société Française des
Sciences et des Techniques Pharmaceutiques” (SFSTP) regarding
bioanalytical methods and adapted to our specific requirements
(Boulanger et al., 2003; Peters et al., 2007; Lynch, 2016). Two
product ions (one quantifier and one qualifier) were used for
data processing (Table 1) and full MS/MS spectra were compared
with the online advanced mass spectral database m/z cloud. The
validation was performed over 3 non-consecutive days (p =
3). The trueness and precision were evaluated using a variance
analysis-based statistical treatment (ANOVA). Calibration (Cal)
was performed in duplicate at 5 different concentration levels
(k = 5) (Table 1) while quality controls (QCs) were prepared in
quadruplicate at the two lowest and highest concentration levels
(k = 4). Using the acquired data, trueness, precision, accuracy,
linearity, limits of detection (LOD), and quantification (LOQ)
were determined. Six different blank bloods were analyzed for
selectivity assessment investigating for potential interferences.
The approach developed by Matuszweski et al. was used for
recovery (RE) and matrix effect (ME) evaluation (Matuszewski
et al., 2003). In this optic, three sample sets were prepared,
including all the substances of interest at two concentration
levels (low being level 2 and high being level 4 described in
Table 1). Sample set 1 represented neat standards spiked after
FIGURE 1 | Chromatographic separation at LOQ (calibration level 1) using retention time windows to ensure a sufficient number of acquisition points for
proper quantification.
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TABLE 2 | Results for trueness, precision, and linearity (k is the number of
concentration levels, n the number of repetitions by levels, and p the number of
non-consecutive days).
Trueness (%) (k = 4; n = 4; p = 3)
Calibration level (ng/ml) Level 1 Level 2 Level 4 Level 5
THC 107.3 98.4 101.8 106.2
THC-COOH 100.9 104.2 102.4 101.9
Cocaine 101.4 102.2 103.0 103.3
Cocaethlyene 102.1 106.7 101.1 99.4
Benzoylecgonine 101.8 103.6 100.6 99.8
Amphetamine 107.7 104.8 101.5 100.7
Methamphetamine 102.9 101.2 100.6 97.2
MDA 104.4 105.3 103.4 98.2
MDMA 107.2 102.2 97.6 98.3
Methylephenidate 104.8 103.4 102.4 100.6
Morphine 101.6 96.1 100.8 100.6
Codeine 103.5 107.6 103.2 102.4
Methadone 107.6 103.5 104.4 100.5
Tramadol 103.8 98.5 100.4 99.6
O-Desmethyltramadol 98.9 100.5 98.1 99.5
Diazepam 97.6 101.7 103.2 96.7
Nordazepam 98.4 102.6 103.0 99.6
Oxazepam 98.7 98.1 100.0 97.0
Lorazepam 101.0 99.5 99.3 102.2
Bromazepam 95.3 101.1 97.1 100.3
Alprazolam 100.9 105.1 101.8 97.2
Repeatability/intermediate precision (RSD %) (k = 4, n = 4, p = 3)
Calibration level (ng/ml) Level 1 Level 2 Level 4 Level 5
THC 5.6/5.6 3.1/3.9 3.9/4.0 3.2/7.1
THC-COOH 7.4/8.3 7.2/7.2 4.5/4.5 5.7/5.7
Cocaine 7.8/7.8 4.0/7.0 7.0/7.0 3.6/6.3
Cocaethlyene 3.6/5.7 4.7/5.0 2.2/2.3 4.5/4.5
Benzoylecgonine 5.0/5.0 2.4/3.3 2.2/2.2 3.1/3.5
Amphetamine 7.9/7.9 5.6/7.6 4.7/6.5 5.5/5.5
Methamphetamine 6.7/7.0 7.1/7.1 4.0/5.7 5.5/5.5
MDA 4.6/5.6 4.8/7.7 3.0/3.0 3.7/3.7
MDMA 5.2/6.9 6.8/6.8 4.8/4.8 6.4/4.7
Methylephenidate 3.6/4.1 4.1/5.6 3.1/3.7 3.8/3.8
Morphine 3.9/7.9 3.7/3.7 2.2/2.2 1.1/1.5
Codeine 7.2/8.4 5.3/6.3 5.0/6.2 2.8/4.8
Methadone 8.3/8.3 5.3/5.3 7.7/7.7 4.4/4.4
Tramadol 3.6/3.6 6.5/6.5 5.9/5.9 3.1/3.1
O-Desmethyltramadol 6.4/6.9 4.0/4.0 5.6/5.6 3.3/3.3
Diazepam 11.2/11.2 4.6/5.4 3.9/4.2 5.3/5.3
Nordazepam 3.8/4.2 3.1/3.2 2.2/2.2 1.9/2.2
Oxazepam 4.3/4.3 5.9/5.9 6.6/7.4 3.0/4.8
Lorazepam 8.4/11.0 5.5/5.5 9.4/9.8 4.6/6.5
Bromazepam 11.6/11.6 3.7/3.8 3.6/3.6 2.5/2.5
Alprazolam 9.0/9.0 5.2/5.6 7.0/7.0 3.8/4.2
(Continued)
TABLE 2 | Continued





THC 1–20 1.0623 0.9928 1
THC-COOH 5–100 1.0188 0.9946 5
Cocaine 10–200 1.0339 0.9933 10
Cocaethlyene 50–1,000 0.9905 0.9970 50
Benzoylecgonine 50–1,000 0.9959 0.9980 50
Amphetamine 10–200 1.0044 0.9937 10
Methamphetamine 10–200 0.9711 0.9944 10
MDA 10–200 0.9802 0.9967 10
MDMA 10–200 0.9779 0.9934 10
Methylephenidate 10–200 1.0046 0.9972 10
Morphine 5–2,000 1.0063 0.9995 5
Codeine 5–2,000 1.0237 0.9962 5
Methadone 5–2,000 1.0077 0.9951 5
Tramadol 5–2,000 0.9966 0.9978 5
O-Desmethyltramadol 5–2,000 0.9934 0.9977 5
Diazepam 5–2,000 0.9688 0.9936 5
Nordazepam 5–2,000 0.9969 0.9987 5
Oxazepam 5–2,000 0.9707 0.9945 5
Lorazepam 20–300 0.9921 0.9921 20
Bromazepam 20–300 1.0032 0.9980 20
Alprazolam 5–100 0.9697 0.9948 5
Zolpidem 40–600 1.0019 0.9983 40
the extraction, while sample set 2 represented blank blood
spiked after extraction. Sample set 3 represented blank blood
spiked before extraction. The absence of interfering peaks at the
established retention times (RT) for the analytes and the IS was
used to ensure the specificity. The chemical stability of all analytes
was evaluated under sample handling and storage conditions at
low and high concentrations in five replicates. Benchtop (6 h,
room temperature), autosampler (24 h, 5◦C), three cycles of
freeze-thaw (−20◦C), and short term (1 week,−20◦C) conditions
were used for stability determination.
In order to evaluate the method, 8 different EQCs were
analyzed in duplicates using the exact same procedure.
RESULTS AND DISCUSSION
Method Development
In the present study, 22 analytes (15 IS) included in the
main classes of drugs of abuse, as well as the major
benzodiazepines, were analyzed using a single simultaneous
multi-analyte quantitative approach. This list of substances was
established based on the FEDRO recommendations and on the
knowledge of the prevalence of psychoactive compounds among
suspected impaired drivers. A nationwide study performed
on 4,668 samples collected on suspected drivers in 2010 in
Switzerland proved cannabinoids (48%), alcohol (35%), cocaine
(25%), opiates (15%), amphetamines (7%), and benzodiazepines
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(6%) to be the most detected substances (Senna et al., 2010). The
use of such multi-analyte approaches is challenging due to the
various physico-chemical properties of the substances of interest
and requires specific care duringmethod development. To ensure
a proper quantification, retention time windows were set for
the acquisition ensuring the acquisition of a sufficient number
of acquisition points (Figure 1). For good-quality integration
and reproducible quantification, a minimum of 10–15 points is
necessary to define exactly the peak start, peak apex, and peak
end. The method was designed to resolve the wide majority of
DUID cases using a single procedure and a limited amount of
biological sample (Supplemental Figure 1) (Senna et al., 2010).
The method allows the successful PRM-based quantification
of cannabinoids, amphetamines, cocaine and its metabolites,
opiates and opioids, and the major benzodiazepines at the
sensitivity necessary for legal thresholds and therapeutic ranges
(OOCCR-OFROU, 2008; Schulz et al., 2012).
Trueness and Precision
Independent QC samples at 4 different calibration levels were
injected in 4 replicates over 3 non-consecutive days for the
determination of trueness and precision. Accuracy represents
the total error and is divided into trueness (representing the
“bias” or the systematic error) and precision (referring as the
standard deviation or random errors) (Gonzalez et al., 2010). The
trueness can be evaluated by calculating the percentage difference
between the experimental and the expected theoretical values.
In the present study, the systematic error varied from −4.7
to 7.6% (Table 2). Precision was divided into two parameters:
TABLE 3 | Results for Recovery and Matrix Effect performed at low- and
high-quality control concentrations.









THC −51% (15) 78% (18) −34% (16) 81% (12)
THC-COOH −7% (9) 57% (10) −4% (3) 49% (4)
Cocaine −25% (8) 92% (8) −26% (8) 94% (10)
Cocaethlyene −27% (6) 91% (6) −21% (6) 95% (9)
Benzoylecgonine −22% (4) 91% (6) −19% (8) 92% (8)
Amphetamine −10% (12) 96% (12) −13% (7) 86% (12)
Methamphetamine −12% (11) 76% (10) −18% (12) 75% (10)
MDA −32% (8) 106% (8) −22% (5) 89% (7)
MDMA −35% (10) 96% (9) −18% (8) 95% (7)
Methylephenidate −30% (8) 82% (17) −25% (16) 81% (10)
Morphine −23% (9) 96% (5) −12% (4) 86% (17)
Codeine −27% (4) 96% (16) −13% (6) 95% (7)
Methadone −21% (11) 94% (8) −13% (10) 97% (9)
Tramadol −27% (10) 88% (17) −15% (6) 82% (19)
O-Desmethyltramadol −29% (14) 81% (12) −15% (8) 95% (13)
Diazepam −30% (5) 73% (5) −10% (11) 67% (10)
Nordazepam 0% (11) 82% (9) −4% (9) 86% (9)
Oxazepam −13% (6) 86% (7) −5% (10) 82% (9)
Lorazepam −7% (7) 80% (6) 3% (13) 95% (6)
Bromazepam −18% (9) 96% (8) −15% (10) 105% (7)
Alprazolam −4% (12) 81% (6) −1% (7) 84% (9)
Zolpidem −16% (7) 73% (15) −11% (13) 86% (12)
FIGURE 2 | Accuracy profile for the main classes of drugs of abuse regulated by FEDRO [Cocaine (A), Amphetamine (B), Morphine (C), and THC (D)].
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TABLE 4 | Three cycles of freeze-thaw (−20◦C), benchtop (6 h, room temperature), autosampler (24 h, 5◦C), and short-term (1 week, −20◦C) conditions were performed










Low (CV %) High (CV %) Low (CV %) High (CV %) Low (CV %) High (CV %) Low (CV %) High (CV%)
THC 100% (13) 93% (3) 92% (7) 95% (5) 108% (11) 98% (2) 99% (17) 98% (4)
THC-COOH 103% (7) 97% (4) 106% (8) 97% (8) 100% (11) 101% (5) 101% (7) 99% (2)
Cocaine 109% (7) 95% (6) 99% (12) 92% (7) 104% (10) 99% (6) 108% (12) 96% (7)
Cocaethlyene 107% (12) 96% (6) 99% (12) 92% (16) 93% (6) 95% (14) 88% (9) 94% (8)
Benzoylecgonine 102% (7) 95% (4) 97% (11) 97% (6) 99% (9) 98% (3) 104% (7) 95% (4)
Amphetamine 100% (3) 95% (11) 100% (6) 96% (8) 95% (2) 96% (8) 93% (2) 91% (6)
Methamphetamine 103% (15) 100% (9) 95% (11) 97% (14) 92% (7) 103% (5) 105% (21) 96% (12)
MDA 104% (13) 98% (6) 95% (5) 86% (8) 101% (11) 101% (7) 109% (21) 96% (7)
MDMA 108% (10) 98% (5) 101% (6) 97% (5) 106% (10) 104% (6) 108% (16) 96% (6)
Methylephenidate 109% (21) 106% (13) 106% (10) 92% (19) 105% (10) 106% (16) 109% (20) 108% (16)
Morphine 91% (2) 98% (4) 94% (8) 100% (14) 90% (7) 104% (4) 86% (8) 98% (3)
Codeine 108% (10) 104% (6) 97% (5) 106% (7) 104% (8) 110% (9) 103% (9) 105% (9)
Methadone 106% (6) 98% (17) 96% (6) 101% (14) 99% (6) 105% (5) 102% (4) 98% (3)
Tramadol 108% (11) 98% (7) 102% (6) 100% (7) 98% (9) 105% (8) 100% (10) 98% (9)
O-Desmethyltramadol 99% (10) 101% (6) 98% (9) 101% (9) 99% (6) 106% (11) 96% (9) 94% (7)
Diazepam 104% (6) 97% (6) 101% (8) 88% (7) 90% (6) 96% (9) 102% (5) 90% (9)
Nordazepam 107% (4) 103% (4) 105% (7) 104% (3) 94% (7) 102% (5) 99% (7) 97% (5)
Oxazepam 102% (4) 99% (3) 95% (9) 95% (6) 86% (9) 107% (5) 113% (8) 109% (10)
Lorazepam 97% (16) 98% (6) 85% (7) 93% (11) 94% (10) 108% (6) 110% (8) 106% (8)
Bromazepam 98% (10) 95% (4) 91% (3) 91% (6) 104% (17) 97% (3) 97% (7) 98% (4)
Alprazolam 106% (9) 97% (11) 96% (6) 90% (8) 99% (9) 95% (8) 104% (9) 100% (6)
Zolpidem 109% (10) 93% (9) 92% (8) 93% (10) 115% (10) 97% (6) 97% (7) 94% (6)
FIGURE 3 | Method evaluation by comparing measured values and targeted commercial EQCs values. PRM measured concentrations are plotted as a function of the
expected EQCs concentrations. The red lines represent the ±20% tolerance limits.
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the relative standard deviation (repeatability or RR.S.D.) and the
inter-day variability (intermediate precision or IPR.S.D.). RR.S.D.
represents the variability under similar conditions, meaning that
the analyses are performed by the same operator using the same
reagents and samples. On the other hand, IPR.S.D. represented
the variability associated with the use of the same samples on
different days with different reagents. Precision parameters were
evaluated to be between 1.1 and 11.6% (Table 2). Accuracy
profiles are visual representations combining both the trueness
and the precision to represent the uncertainty measurement
(Figure 2). Precision is represented by the calculated confidence
limit at 95% at each concentration level. Accuracy profiles
also include the representation of acceptance limits of ±20%
at the LLOQ suggested for method validation (±15% at the
other calibration levels). All analyzed QCs were within the
acceptance limits.
Linearity and LOQ
The definition of linearity stands as the method capacity to
provide a result proportional to the actual sample concentration.
To determine this parameter, a linear regression model based on
the least square method was applied on the fit of the obtained
concentration as a function of the theorical concentration.
Slopes values were comprised between 0.9688 and 1.0623 with
coefficients of determination above 0.9921 for all the compounds
confirming the method linearity within the concentration ranges
of interest (Table 2). LOQs were fixed according to the lowest
point of the calibration curve (Table 1).
Selectivity, Recovery, and Matrix Effect
Selectivity is defined as the ability to differentiate the analyte
of interest from potential interferences. To assess the good
selectivity of the method, six different blank blood samples
were analyzed using the complete extraction procedure. No
compounds impairing the detection and quantification of the
analytes of interest were observed. HRMS technology offers a
high selectivity due to its resolving power, therefore reducing
the number of potential interferences (Chindarkar et al., 2014).
However, ME, including ion suppression or enhancement, are
often associated with the use of ESI as ion source challenging the
method selectivity. The determination of such ME is therefore
crucial to ensure a proper detection and quantification of the
substances of interest. ME ranged from −51% (15% CV) of ion
suppression for THC at low concentration and 3% (13% CV)
of ion enhancement for lorazepam, being consistent with the
existing literature (Table 3) (Simonsen et al., 2010; Fernandez
Mdel et al., 2013; Montenarh et al., 2014; Steuer et al., 2014;
Vaiano et al., 2016; De Boeck et al., 2017). All values concerning
RE and ME are summarized in Table 3. To compensate for those
undesirable ME, isotopically-labeled internal standards was used
for normalization.
Stability
Results regarding analytes’ stability are listed in Table 4. Overall,
stability ranged between 86 and 115%, assuring that the samples
were stables within the tested conditions (auto-sampler, bench-
top, 3 cycles of freeze-thaw and short-term stability.
External Quality Control Analysis
Eight commercial EQCs were analyzed in duplicates to ensure the
robustness of the developed method and procedure. In total, the
quantification was performed on 28 samples of amphetamines,
24 samples of cocaine and its metabolites, 16 samples of
cannabinoids, 36 samples of opioids and opiates, and 28 samples
of benzodiazepines and z-drugs. Results comparison between the
described method and the expected EQCs values are represented
in Figure 3 for the different classes of molecules involved in
DUID cases. A good correlation was observed between the
expected and the obtained values. The relative standard deviation
was lower than 20% for all tested substances, confirming
the efficiency of the PRM quantitative acquisition mode for
toxicological analyses. This method confirms the potential of
PRM as a solid alternative to classical MRM approaches (Li et al.,
2016; Lv et al., 2018; Joye et al., 2020).
CONCLUSION
A quick and efficient multi-analyte procedure was successfully
developed in whole blood for the simultaneous quantification
of 37 substances of interest in DUID cases. PRM represents an
interesting alternative to classical MRM quantitative analyses,
with the capability of precisely quantifying a large panel of
substances with similar performance in terms of linearity,
dynamic range, precision, and repeatability (Rauniyar, 2015).
PRM quantification does not require a priori selection of
the fragments of interest, leading to a simplified method
development and better control over the quantification
experiment, especially regarding multi-analyte approaches.
The quantitative PRM procedure presented herein benefits the
increased selectivity and sensitivity brought by HRMS, offering a
clear alternative for quantitative toxicological analyses.
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